| Abstract: | CJC‐1295 is a peptide‐based drug that stimulates the production of growth hormone (GH) from the pituitary gland. It incorporates a functional maleimido group at the C‐terminus that allows it to covalently bind plasma proteins such as serum albumin. These CJC‐1295‐protein conjugates have a much greater half‐life compared to the unconjugated peptide and are capable of stimulating GH production for more than six days in humans after a single administration. Conjugated CJC‐1295 is difficult to detect in blood by mass spectrometry due to its low abundance, high molecular weight, and conjugation to a range of different protein substrates. Previously we described a screening procedure for the detection of CJC‐1295 in equine plasma using an immuno‐PCR assay. Here we demonstrate the confirmation of CJC‐1295 in equine plasma by LC?MS/MS after immuno‐affinity capture and tryptic digestion. Using this method, CJC‐1295 was identified down to concentrations as low as 180 pg/mL in 1 mL of equine plasma. |
